Pfizer Inc. (NYSE:PFE) Shares Sold by Colton Groome Financial Advisors LLC

Colton Groome Financial Advisors LLC cut its stake in Pfizer Inc. (NYSE:PFE) by 4.2% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 11,867 shares of the biopharmaceutical company’s stock after selling 521 shares during the period. Colton Groome Financial Advisors LLC’s holdings in Pfizer were worth $315,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the stock. Retirement Wealth Solutions LLC purchased a new stake in shares of Pfizer during the 4th quarter valued at $26,000. Gladius Capital Management LP boosted its holdings in Pfizer by 102.8% in the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 38,015 shares during the last quarter. Quarry LP purchased a new stake in Pfizer during the second quarter valued at about $31,000. Teachers Insurance & Annuity Association of America acquired a new stake in Pfizer during the third quarter worth about $35,000. Finally, Joseph Group Capital Management raised its holdings in shares of Pfizer by 168.3% in the 3rd quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 771 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Performance

Shares of PFE opened at $26.60 on Thursday. The firm has a market cap of $150.75 billion, a price-to-earnings ratio of 36.04, a PEG ratio of 0.64 and a beta of 0.64. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The business’s 50 day moving average is $26.18 and its two-hundred day moving average is $27.91. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. The firm had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The firm’s revenue was up 31.2% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.17) EPS. Analysts forecast that Pfizer Inc. will post 2.94 EPS for the current fiscal year.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be given a dividend of $0.43 per share. This is a boost from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.47%. Pfizer’s dividend payout ratio (DPR) is presently 227.03%.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. Bank of America reiterated a “neutral” rating and set a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. Guggenheim decreased their price objective on shares of Pfizer from $35.00 to $33.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Truist Financial cut their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. StockNews.com cut shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Finally, Evercore ISI raised Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.